April 2026 in “Journal of Exercise Rehabilitation” This report describes a case where a woman's hair loss following COVID-19 vaccination improved after treatment with autologous CD34+ hematopoietic progenitor cells and umbilical cord blood-derived mesenchymal stem cells, with no significant adverse effects observed over the 12-week treatment period.
561 citations
,
April 2003 in “Journal of Investigative Dermatology” CD34 is a marker for isolating stem-like cells in mouse hair follicles.
235 citations
,
January 2011 in “Journal of Clinical Investigation” This study found that androgenetic alopecia may involve a defect in the conversion of hair follicle stem cells to progenitor cells, as demonstrated by a reduced presence of progenitor cells in bald scalp samples.
141 citations
,
May 2007 in “Cancer Research” This study found that CD34 is necessary for TPA-induced activation of hair follicle stem cells and tumor formation in mice, with CD34 knockout mice showing delayed and reduced tumor development compared to wild-types.
88 citations
,
December 2012 in “Journal of The European Academy of Dermatology and Venereology” This study found that interfollicular injection of autologous CD34+ cell-containing PRP preparation improved hair count and thickness in patients with pattern hair loss, with better results than placental extract treatment.